Published in AIDS Care on August 01, 2000
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr (2006) 3.93
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues. AIDS Behav (2007) 2.20
Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol (2007) 1.46
Caregivers' Attitudes towards HIV Testing and Disclosure of HIV Status to At-Risk Children in Rural Uganda. PLoS One (2016) 1.45
Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav (2013) 1.41
Patient-related factors predicting HIV medication adherence among men and women with alcohol problems. J Health Psychol (2007) 1.38
Trust in physicians and racial disparities in HIV care. AIDS Patient Care STDS (2010) 1.33
Does long-term medication use improve the academic outcomes of youth with attention-deficit/hyperactivity disorder? Clin Child Fam Psychol Rev (2012) 1.31
Antiretroviral adherence during pregnancy and postpartum in Latin America. AIDS Patient Care STDS (2012) 1.20
A comparison of adherence assessment methods utilized in the United States: perspectives of researchers, HIV-infected children, and their caregivers. AIDS Patient Care STDS (2009) 1.18
What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol (2014) 1.11
Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting. AIDS Care (2010) 1.05
Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients. Ther Clin Risk Manag (2011) 0.93
TextTB: A Mixed Method Pilot Study Evaluating Acceptance, Feasibility, and Exploring Initial Efficacy of a Text Messaging Intervention to Support TB Treatment Adherence. Tuberc Res Treat (2013) 0.88
A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol (2016) 0.87
Medication diaries do not improve outcomes with highly active antiretroviral therapy in Kenyan children: a randomized clinical trial. J Int AIDS Soc (2009) 0.85
Patterns of substance use among HIV-positive adults over 50: implications for treatment and medication adherence. Drug Alcohol Depend (2014) 0.85
Understanding the Impact of Hazardous and Harmful Use of Alcohol and/or Other Drugs on ARV Adherence and Disease Progression. PLoS One (2015) 0.84
High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int (2015) 0.84
Retention in care and medication adherence: current challenges to antiretroviral therapy success. Drugs (2015) 0.82
High Concordance between Self-Reported Adherence, Treatment Outcome and Satisfaction with Care Using a Nine-Item Health Questionnaire in InfCareHIV. PLoS One (2016) 0.81
Medication understanding, non-adherence, and clinical outcomes among adult kidney transplant recipients. Clin Transplant (2016) 0.78
Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health (2014) 0.78
Gender Differences in Psychosocial Factors Associated with HIV Viral Suppression Among African-American Injection Drug Users. AIDS Behav (2016) 0.75
Text Messaging to Improve Hypertension Medication Adherence in African Americans From Primary Care and Emergency Department Settings: Results From Two Randomized Feasibility Studies. JMIR Mhealth Uhealth (2017) 0.75
A Randomized Controlled Trial of Rise, a Community-Based Culturally Congruent Adherence Intervention for Black Americans Living with HIV. Ann Behav Med (2017) 0.75
Live events, stress, and illness. Science (1976) 3.05
Wish to die in end-stage ALS. Neurology (2005) 2.97
Heterogeneity of clinical response during placebo treatment. Am J Psychiatry (1991) 2.06
Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry (1984) 1.66
Different types of placebo response in patients receiving antidepressants. Am J Psychiatry (1991) 1.40
Medical and dental students' attitudes about the AIDS epidemic. Acad Med (1990) 1.32
Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl (1993) 1.26
Psychopathology in male and female intravenous drug users with and without HIV infection. Am J Psychiatry (1994) 1.22
Hypertension and DSM-III depression in psychiatric outpatients. Am J Psychiatry (1983) 1.20
Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. Am J Drug Alcohol Abuse (1999) 1.20
Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry (1991) 1.17
How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res (1986) 1.15
The relationship between employment and neuropsychological impairment in HIV infection. J Int Neuropsychol Soc (1999) 1.15
Validity of clinical trials of antidepressants. Am J Psychiatry (2000) 1.14
Ethnic density and psychiatric hospitalization: hazards of minority status. Am J Psychiatry (1979) 1.10
Treatment of premenstrual dysphoria with alprazolam and placebo. Psychopharmacol Bull (1987) 1.08
Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry (2009) 1.07
Antidepressant specificity in atypical depression. Arch Gen Psychiatry (1988) 1.07
Disparities in perceptions of distress and burden in ALS patients and family caregivers. Neurology (2004) 1.03
Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv (1998) 1.02
Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry (1988) 1.01
The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med (1998) 1.01
Atypical depression. A valid clinical entity? Psychiatr Clin North Am (1993) 1.00
Hopelessness as a mediator of the association between social support and depressive symptoms: findings of a study of men with HIV. J Consult Clin Psychol (2001) 0.96
Stressful life events and schizophrenia: a review of the research literature. Psychol Bull (1980) 0.96
Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. Compr Psychiatry (1999) 0.93
Duration of antidepressant drug treatment. What is an adequate trial? Arch Gen Psychiatry (1984) 0.93
Study duration in antidepressant research: advantages of a 12-week trial. J Psychiatr Res (1986) 0.93
Anxiety syndromes and symptoms among men with AIDS: a longitudinal controlled study. Psychosomatics (2000) 0.92
Dehydroepiandrosterone sulfate (DHEAS) and testosterone: relation to HIV illness stage and progression over one year. J Acquir Immune Defic Syndr (1999) 0.91
Axis I psychiatric symptoms associated with HIV infection and personality disorder. Am J Psychiatry (1995) 0.91
Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry (1990) 0.91
Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord (1998) 0.90
Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry (1991) 0.90
Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol (1986) 0.89
Bipolar disorder: are there manic-prone and depressive-prone forms? J Clin Psychopharmacol (1986) 0.89
Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res (1997) 0.88
Sexual risk behavior changes among HIV+ and HIV-female injecting drug users over 4 years. Women Health (1998) 0.88
Chronic depression: response to placebo, imipramine, and phenelzine. J Clin Psychopharmacol (1993) 0.88
Opinions about mental illness: a review of the literature. Psychol Bull (1972) 0.88
A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry (1993) 0.87
Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol (1992) 0.87
Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry (1989) 0.87
A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients. Compr Psychiatry (1997) 0.87
Mental health needs assessment. A review of methods. Med Care (1986) 0.86
Criminal behavior of discharged mental patients: a critical apprasial of the research. Psychol Bull (1979) 0.86
Loss of drug effects during continuation therapy. Am J Psychiatry (1993) 0.85
Treatment of premenstrual dysphoric changes: clinical outcome and methodological implications. Psychopharmacol Bull (1984) 0.85
Sexual activity among HIV-seropositive gay men seeking treatment for depression. J Clin Psychiatry (1993) 0.84
Disease severity, physical limitations and depression in HIV-infected men. J Psychosom Res (1998) 0.84
Side effect assessment with SAFTEE: pilot study of the instrument. Psychopharmacol Bull (1986) 0.84
Psychological and physical health correlates of body cell mass depletion among HIV+ men. J Psychosom Res (2000) 0.83
Sleep of atypical depressives. J Affect Disord (1985) 0.83
What the neighbors think: community attitudes toward local psychiatric facilities. Community Ment Health J (1984) 0.82
Development of the Impact of Weight Loss Scale (IWLS): a psychometric study in a sample of men with HIV/AIDS. AIDS Care (1999) 0.82
Treating depression in HIV-positive patients. AIDS (1994) 0.82
Stability and change in personality disorder symptomatology: findings from a longitudinal study of HIV+ and HIV- men. J Abnorm Psychol (1997) 0.82
Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry (1993) 0.82
A female perspective on living with HIV disease. Health Soc Work (2001) 0.81
Defining the boundaries of atypical depression. J Clin Psychiatry (1984) 0.81
Personality disorders predict onset of Axis I disorders and impaired functioning among homosexual men with and at risk of HIV infection. Arch Gen Psychiatry (1996) 0.81
Illness stage, concurrent medications, and other correlates of low testosterone in men with HIV illness. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.81
Adhering to complex regimens for HIV. GMHC Treat Issues (1998) 0.80
Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry (1999) 0.80
Follow-up of patients who improved during placebo washout. J Clin Psychopharmacol (1986) 0.79
Remission of substance use disorders: gay men in the first decade of AIDS. J Stud Alcohol (1995) 0.79
Baseline characteristics of 10-day placebo washout responders in antidepressant trials. Psychiatry Res (1987) 0.79
Psychological aspects of living with HIV disease: a primary care perspective. West J Med (2001) 0.79
Bereavement reactions among homosexual men experiencing multiple losses in the AIDS epidemic. Am J Psychiatry (1992) 0.78
Measuring medication adherence: is assessment of missed doses sufficient? AIDS (1999) 0.78
Treatment outcome validation of DSM-III depressive subtypes. Clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry (1985) 0.78
Psychiatric evaluation of premenstrual changes. Psychosomatics (1985) 0.78
Psychological distress and natural killer cells in gay men with and without HIV infection. Am J Psychiatry (1994) 0.78
Health locus of control, distress, and utilization of protease inhibitors among HIV-positive men. J Psychosom Res (2000) 0.77
Characteristics of women seeking treatment for premenstrual syndrome. Psychosomatics (1989) 0.77
l-Deprenyl in atypical depressives. Arch Gen Psychiatry (1984) 0.77
Social functioning in chronic depression: effect of 6 weeks of antidepressant treatment. Psychiatry Res (1988) 0.77
Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull (1989) 0.77
Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. J Clin Psychopharmacol (1985) 0.76
Testosterone therapy for clinical symptoms of hypogonadism in eugonadal men with AIDS. Int J STD AIDS (1998) 0.76
Who is called mentally ill: public and professional views. J Community Psychol (1979) 0.76
Testosterone as a treatment for fatigue in HIV+ men. Gen Hosp Psychiatry (1998) 0.76
Methodological problems in studies of depressive disorder: utility of the discontinuation design. J Clin Psychopharmacol (1981) 0.76
The concurrent validity of items in the Quality-of-Life Index in a cohort of HIV-positive and HIV-negative gay men. Control Clin Trials (1991) 0.75
Placebo-controlled study of mianserin in depressed outpatients. Neuropsychobiology (1985) 0.75
The dexamethasone suppression test with mildly to moderately depressed outpatients. Am J Psychiatry (1983) 0.75
Psychopharmacological dissection of nonendogenous depression. Psychopharmacol Bull (1984) 0.75
Testosterone, illness progression, and megestrol use in HIV-positive men. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.75
Long-term testosterone therapy in HIV-positive men: side-effects and maintenance of clinical benefit. AIDS (1998) 0.75
Immunologic effects of psychotropic drugs in HIV+ patients. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.75
Evaluation of a mental health consultation service in a ghetto area. Am J Psychother (1970) 0.75
Attrition and its consequences in a clinical trial of placebo, imipramine, and phenelzine. Psychopharmacol Bull (1985) 0.75
Factors associated with premature medication discontinuation among responders to an MAOI or a tricyclic antidepressant. J Clin Psychiatry (1988) 0.75
Validity assessment of SAFTEE: a preliminary report. Psychopharmacol Bull (1987) 0.75
The epidemiology of forcible rape. Am J Orthopsychiatry (1979) 0.75
Difficulties in interpersonal relationships associated with personality disorders and axis I disorders: a community-based longitudinal investigation. J Pers Disord (2000) 0.75
Cortisol response to dextroamphetamine stimulation in depressed outpatients. Psychiatry Res (1984) 0.75
Psychopharmacologic validation of atypical depression. J Clin Psychiatry (1984) 0.75
Mianserin versus amitriptyline for depression: a double-blind 6-week trial. Neuropsychobiology (1984) 0.75
Effects of testosterone upon body composition. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.75